Strong growth for STADA Group in 2025 as well

The STADA Group, of which Hemofarm is a part, achieved growth across all three segments in 2025 – Specialty Pharmaceuticals, Consumer Healthcare, and Generics. STADA Group's adjusted revenues increased by 6%, reaching €4.3 billion, while adjusted EBITDA, measured at constant exchange rates, improved by 8% to €961 million.

"All our regions – Western, Central and Eastern Europe, Germany, the Middle East and Asia – are contributing strongly to overall company growth. Above-industry-average growth has been driven by a series of successful launches across all three business segments. At the same time, in 2025 we enriched our portfolio with more than 110 newly licensed products, further strengthening our development pipeline and the foundation for future growth," said STADA Group CEO Peter Goldschmidt.

Specialty segment surpasses one billion euros: Revenue from the Specialty segment, led by biosimilars and innovative medicines, exceeded €1 billion for the first time in 2025, growing by 17% and now accounting for nearly one quarter of the Group's total revenue. Key drivers include continued growth of the existing biosimilar portfolio across a wide range of therapeutic areas such as bone health, immunology, and oncology. Five new biosimilar launches are planned for this year, further strengthening STADA Group's position as a leader in Europe.

Generics growth: Revenue from the Generics segment grew by 5% in 2025 (adjusted at constant exchange rates), with the segment continuing to outperform the market in Europe. Successful launches and commercial synergies further solidified the company's position among the top three market players in the retail generics segment across key European markets, including Germany, Italy, Spain, Belgium, Ireland, the Nordic countries, Serbia, and Switzerland.

Local brands drive growth: The Consumer Healthcare segment delivered solid results last year, with revenue growth of 2%. Outside the cough and cold category, STADA achieved mid-single-digit growth and nearly doubled its eCommerce sales between 2022 and 2025.

€50 million investment in Hemofarm: As highlighted by Ronald Zeliger, CEO of Hemofarm, during 2025 Hemofarm acquired the Fortacell and Biota Intima brands in Serbia, while the EUNOVA brand was launched in Bosnia and Herzegovina.

"We continue our strong growth in the Western Balkans region, and in 2025 alone the STADA Group invested over €50 million – in new equipment and innovative machinery, as well as in registrations and licenses," Zeliger noted, adding that since STADA Group acquired Hemofarm in 2006 through the end of last year, nearly €530 million has been invested in the company.

Evaluating potential acquisitions globally: "We are actively analyzing potential acquisitions worldwide to further strengthen the growth of the Consumer Healthcare segment. At the same time, we continue to expand our brand portfolio in the fastest-growing categories, including dermatology, preventive health, and wellness," Goldschmidt said, adding: "Our oncology pipeline has significant potential, containing molecules such as enzalutamide and ruxolitinib, and we also have apixaban and edoxaban to complement our ongoing rivaroxaban launch in the cardiovascular category. Through 110 business development and licensing engagements signed in 2025, along with continued development and a network of licensing partnerships, we have built a pipeline with significant potential for the coming years. We are fully prepared, with a clearly defined strategy arising from the loss of exclusivity of GLP-1 therapies, both in diabetes treatment and obesity. In addition, the SGLT-2 inhibitor empagliflozin represents a key development project in diabetes therapies, further strengthening our portfolio of innovative medicines."

Culture drives performance: Goldschmidt highlighted STADA's renewed certification as a "Top Employer Europe," as well as the results of the latest employee satisfaction survey, in which 80% of employees expressed pride in working for the company: "What enables the STADA Group to consistently outperform the market is our unique One STADA spirit and growth culture. The exceptional dedication of our nearly 12,000 employees worldwide – more than half of whom work in Technical Operations, ensuring reliable medicine supply for patients – is the foundation of our continued growth and our commitment to caring for people's health as a trusted partner."